1705 - AAT GVHD Treatment

Go Back to BMT CTN Protocol Listing

  • Protocol Short Name and Number: AAT GVHD Treatment, 1705
  • Protocol Long Name: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 – Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
  • Protocol Synopsis (PDF)
  • ICFs (PDF)
  • FAQs (PDF)
  • Key Personnel
    • BMT CTN # Co-Chair: Amin Alousi
    • BMT CTN # Co-Chair: John Magenau
    • Protocol Officer: Mehdi Hamadani, MD
    • Protocol Coordinator: bmtctn1705@emmes.com
  • Keywords: Alpha-1 Antitrypsin, AAT, Graft versus Host Disease, GVHD, Graft vs. Host Disease, GVHD Treatment, Quality of Life, QOL, Patient Reported Outcomes, PROs, Pediatric, Child, Children, Teen, Adolescent